Literature DB >> 35344339

Do Anti-tuberculosis Drugs Reach Their Target?─High-Resolution Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Provides Information on Drug Penetration into Necrotic Granulomas.

Julia Kokesch-Himmelreich1,2, Axel Treu1,2, Alan M Race1, Kerstin Walter3,2, Christoph Hölscher3,2, Andreas Römpp1,2.   

Abstract

Tuberculosis (TB) is characterized by mycobacteria-harboring centrally necrotizing granulomas. The efficacy of anti-TB drugs depends on their ability to reach the bacteria in the center of these lesions. Therefore, we developed a mass spectrometry (MS) imaging workflow to evaluate drug penetration in tissue. We employed a specific mouse model that─in contrast to regular inbred mice─strongly resembles human TB pathology. Mycobacterium tuberculosis was inactivated in lung sections of these mice by γ-irradiation using a protocol that was optimized to be compatible with high spatial resolution MS imaging. Different distributions in necrotic granulomas could be observed for the anti-TB drugs clofazimine, pyrazinamide, and rifampicin at a pixel size of 30 μm. Clofazimine, imaged here for the first time in necrotic granulomas of mice, showed higher intensities in the surrounding tissue than in necrotic granulomas, confirming data observed in TB patients. Using high spatial resolution drug and lipid imaging (5 μm pixel size) in combination with a newly developed data analysis tool, we found that clofazimine does penetrate to some extent into necrotic granulomas and accumulates in the macrophages inside the granulomas. These results demonstrate that our imaging platform improves the predictive power of preclinical animal models. Our workflow is currently being applied in preclinical studies for novel anti-TB drugs within the German Center for Infection Research (DZIF). It can also be extended to other applications in drug development and beyond. In particular, our data analysis approach can be used to investigate diffusion processes by MS imaging in general.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35344339     DOI: 10.1021/acs.analchem.1c03462

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  3 in total

1.  Mass spectrometry imaging: new eyes on natural products for drug research and development.

Authors:  Jin-Jun Hou; Zi-Jia Zhang; Wen-Yong Wu; Qing-Qing He; Teng-Qian Zhang; Ya-Wen Liu; Zhao-Jun Wang; Lei Gao; Hua-Li Long; Min Lei; Wan-Ying Wu; De-An Guo
Journal:  Acta Pharmacol Sin       Date:  2022-10-13       Impact factor: 7.169

2.  Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections.

Authors:  Margaux Fresnais; Siwen Liang; Marius Breitkopf; Joshua Raoul Lindner; Emmanuelle Claude; Steven Pringle; Pavel A Levkin; Konstantin Demir; Julia Benzel; Julia Sundheimer; Britta Statz; Kristian W Pajtler; Stefan M Pfister; Walter E Haefeli; Jürgen Burhenne; Rémi Longuespée
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-01

3.  Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.

Authors:  Kerstin Walter; Julia Kokesch-Himmelreich; Axel Treu; Franziska Waldow; Doris Hillemann; Nikolas Jakobs; Ann-Kathrin Lemm; Dominik Schwudke; Andreas Römpp; Christoph Hölscher
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.